NEW YORK, December 31, 2014 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
HSP Research Report: ( http://get.analystsreview.com/pdf/?c=Hospira&d=31-Dec-2014&s=HSP ),
AQXP Research Report: ( http://get.analystsreview.com/pdf/?c=Aquinox&d=31-Dec-2014&s=AQXP ),
SCMP Research Report: ( http://get.analystsreview.com/pdf/?c=Sucampo&d=31-Dec-2014&s=SCMP ),
NRX Research Report: ( http://get.analystsreview.com/pdf/?c=NephroGenex&d=31-Dec-2014&s=NRX ),
OGXI Research Report: ( http://get.analystsreview.com/pdf/?c=OncoGenex&d=31-Dec-2014&s=OGXI ).
============
--
Analyst Update: FDA Approvals, Clinical Study Updates, and Agreement
Reviewed by: Rohit Tuli, CFA®
The U.S. stock market ended in red on Tuesday with energy stocks being the worst performers of the day. A less than expected December 2014 consumer confidence index (CCI) figure deterred investor confidence further. The U.S. CCI climbed to 92.6 in December from a revised 91.0 last month, below a post-recession high of 94.1 set in October 2014. The DJIA declined 0.31%, S&P 500 dropped 0.49% and the Nasdaq Composite weakened 0.61% during the session. The European stock market also declined, led by weakness in energy companies as Brent oil fell to a five and a half year low on persistent concerns about a global supply glut. The Asian stock market closed broadly lower too. The Japanese government on Tuesday agreed to a tax reform, approving a plan to cut corporate taxes by 2.51 percentage point from April 2015 and then by another 0.78 percentage points in the following year, in an effort to spur economic growth.
Hospira, Inc. (Hospira) announced that the U.S. Food and Drug Administration (FDA) has approved its non-opioid injection Dyloject (diclofenac sodium) used for management of mild to severe pain in adults. The approval comes at a time when various medical organizations recommend a multi-modal approach to pain control in an effort to minimize the use of opioids. Know more about the Hospira's painkiller in comparison to other non-opioid analgesics in the market in our exclusive research report.
Aquinox Pharmaceuticals Inc. (Aquinox) announced that it has initiated patient dosing in a Phase 2 clinical trial of its lead drug candidate AQX-1125 for the treatment of atopic dermatitis (AD), a disease that currently affects approx. 17.8 million Americans. Discover more about the Aquinox's new Phase-2 clinical trial investigating AQX-1125 in atopic dermatitis in our research report.
Sucampo Pharmaceuticals, Inc. (Sucampo) announced that the Health Canada has accepted its New Drug Submission (NDS) for AMITIZA (lubiprostone) for the treatment of chronic idiopathic constipation in adults and opioid induced constipation in adults with chronic non-cancer pain. Read more on the latest approval for Sucampo's AMITIZA in our research report.
Shares of the U.S.-based drug development company NephroGenex, Inc. (NephroGenex) jumped over two-fold in the after-hours trading on Tuesday, December 30, as the Company reported positive results for QT study of Pyridorin. The study supports use of Pyridorin in patients with diabetic nephropathy - a kidney diseases caused by diabetes affecting approx. 6 million patients in the U.S. Read more about the Company's positive QT study results, along with management's view on the same, in our research report.
OncoGenex Pharmaceuticals Inc., (OncoGenex) announced execution of an initial agreement with Teva Pharmaceutical Industries Ltd. (Teva) to regain rights to Custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers. In addition, OncoGenex said that it will receive a $27 million payment from Teva. Click on our research report to get further insights into the details of this initial agreement between OncoGenex and Teva.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
